Hospital
Presbyterian Medical Center of the University of Pennsylvania Health S
Presbyterian Medical Center of the University of Pennsylvania Health S was paid $23.27M by Medicaid between Jan 2018 and Dec 2024, across 343 billing codes. Its largest line is 99284, emergency room visit (serious) — 17% of everything it billed.
33Billing provider infoPRESBYTERIAN MEDICAL CENTER OF THE UNIVERSITY OF PENNSYLVANIA HEALTH S
PHILADELPHIA, PA 19104
PHILADELPHIA, PA 19104
33aNPI1245207521assigned 03/04/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$23.27M
24GClaims501,397
24DCodes billed343
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Pennsylvania
Rank by total paid#13 of 154
Median peer was paid$2.82M
This provider vs. median8.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 444 | $4K | |
| 2019 | 3,072 | $26K | |
| 2020 | 88,896 | $3.59M | |
| 2021 | 210,865 | $10.02M | |
| 2022 | 54,962 | $3.35M | |
| 2023 | 64,218 | $3.53M | |
| 2024incomplete | 78,940 | $2.75M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 20,024 | 19,074 | $3.94M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 18,809 | 17,768 | $3.72M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 15% | 18,666 | 17,721 | $3.55M |
| G0378 | Hospital observation service, per hour | 11% | 1,943 | 1,825 | $2.45M |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 5.0% | 613 | 585 | $1.17M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.3% | 7,925 | 7,443 | $526K |
| G9012 | Other specified case management service not elsewhere classified | 2.1% | 2,019 | 1,889 | $486K |
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 2.0% | 3,367 | 3,081 | $477K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 1.6% | 3,696 | 2,837 | $365K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.5% | 438 | 420 | $350K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.5% | 3,571 | 3,337 | $344K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.3% | 2,109 | 2,028 | $309K |
331 more codes
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.1% | 395 | $253K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 192 | $216K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,239 | $163K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,541 | $158K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,578 | $156K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,245 | $150K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 163 | $149K |
| 36415 | Collection of venous blood by venipuncture | <1% | 50,031 | $148K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 13,824 | $134K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 804 | $134K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 383 | $122K |
| 73221 | <1% | 340 | $102K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 877 | $98K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 20,094 | $95K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,003 | $94K |
| 87536 | <1% | 1,167 | $91K | |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 28 | $82K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 25,843 | $82K |
| 74183 | <1% | 167 | $80K | |
| 73562 | <1% | 4,558 | $75K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 439 | $75K |
| 73564 | <1% | 3,348 | $74K | |
| 20610 | <1% | 444 | $72K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 398 | $72K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,579 | $69K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,920 | $68K |
| 73610 | <1% | 3,058 | $67K | |
| 72141 | <1% | 285 | $67K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 259 | $65K |
| 70486 | <1% | 545 | $61K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 129 | $60K |
| 72197 | <1% | 118 | $58K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 669 | $56K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 287 | $56K |
| 80053 | Comprehensive metabolic panel | <1% | 11,456 | $52K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 5,897 | $52K |
| 71250 | <1% | 638 | $49K | |
| 73630 | <1% | 3,009 | $43K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 243 | $42K |
| 76881 | <1% | 504 | $41K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,805 | $41K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,602 | $40K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,357 | $40K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,160 | $39K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 403 | $39K |
| 80061 | Lipid panel | <1% | 4,133 | $36K |
| 73030 | <1% | 1,977 | $35K | |
| H0047 | Alcohol and/or other drug abuse services, not otherwise specified | <1% | 435 | $34K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,734 | $33K |
| 93971 | <1% | 612 | $33K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 431 | $33K |
| 73130 | <1% | 2,091 | $33K | |
| 86360 | <1% | 732 | $32K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 2,060 | $31K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,816 | $29K |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 1,117 | $26K |
| 73502 | <1% | 1,231 | $25K | |
| 86359 | <1% | 732 | $25K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,003 | $25K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,826 | $24K |
| 93356 | <1% | 230 | $23K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 339 | $23K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 170 | $21K |
| 82803 | <1% | 1,903 | $21K | |
| 97597 | <1% | 563 | $21K | |
| 70498 | <1% | 161 | $20K | |
| 93017 | <1% | 358 | $19K | |
| 72110 | <1% | 625 | $19K | |
| 96415 | <1% | 508 | $18K | |
| 71045 | Radiologic examination, chest; single view | <1% | 3,009 | $18K |
| 94729 | <1% | 484 | $18K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,035 | $17K |
| 83735 | <1% | 6,248 | $17K | |
| 86480 | <1% | 331 | $16K | |
| 73110 | <1% | 1,058 | $16K | |
| 73700 | <1% | 201 | $16K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 739 | $16K |
| 83880 | <1% | 1,118 | $15K | |
| 76830 | Ultrasound, transvaginal | <1% | 294 | $15K |
| 72100 | <1% | 734 | $15K | |
| 85027 | <1% | 3,871 | $14K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 187 | $14K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 2,487 | $14K |
| 84484 | <1% | 2,680 | $14K | |
| OP710 | <1% | 283 | $14K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,900 | $14K |
| 86803 | <1% | 986 | $14K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 701 | $13K |
| 70496 | <1% | 103 | $13K | |
| 73590 | <1% | 774 | $12K | |
| 82728 | <1% | 1,639 | $12K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,563 | $12K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 2,160 | $12K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 299 | $12K |
| 74246 | <1% | 185 | $11K | |
| 80076 | <1% | 3,099 | $11K | |
| 76536 | <1% | 192 | $11K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 459 | $11K |
| 93970 | <1% | 160 | $11K | |
| 85730 | <1% | 3,161 | $11K | |
| 85610 | <1% | 4,370 | $11K | |
| 96376 | <1% | 330 | $10K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 754 | $10K |
| 86850 | <1% | 2,020 | $10K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,585 | $10K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 438 | $10K |
| 73521 | <1% | 440 | $10K | |
| 20680 | <1% | 12 | $10K | |
| OP250 | <1% | 3,377 | $10K | |
| 94010 | <1% | 732 | $10K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,972 | $9K |
| 70491 | <1% | 84 | $9K | |
| 84466 | <1% | 1,394 | $9K | |
| 93923 | <1% | 187 | $9K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 244 | $9K |
| 72040 | <1% | 412 | $9K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 2,047 | $8K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 2,429 | $8K |
| Q3014 | Telehealth originating site facility fee | <1% | 2,276 | $8K |
| 84100 | <1% | 3,302 | $8K | |
| 36902 | <1% | 31 | $8K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 94 | $7K |
| 73552 | <1% | 399 | $7K | |
| 83605 | <1% | 1,967 | $7K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,715 | $7K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,619 | $7K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 331 | $7K |
| 82607 | <1% | 899 | $7K | |
| 83540 | <1% | 1,483 | $6K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 993 | $6K |
| 84153 | <1% | 450 | $6K | |
| 80320 | <1% | 1,023 | $6K | |
| 86900 | <1% | 2,177 | $6K | |
| 84702 | <1% | 784 | $6K | |
| 94726 | <1% | 213 | $6K | |
| 76770 | <1% | 141 | $6K | |
| 77002 | <1% | 185 | $6K | |
| 81025 | <1% | 3,312 | $6K | |
| 77080 | <1% | 115 | $6K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 34 | $6K |
| 86592 | <1% | 2,403 | $5K | |
| 86901 | <1% | 2,078 | $5K | |
| 76801 | <1% | 112 | $5K | |
| 82570 | <1% | 1,338 | $5K | |
| 83970 | <1% | 224 | $5K | |
| 73080 | <1% | 417 | $5K | |
| 87631 | <1% | 93 | $5K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 29 | $5K |
| 82962 | <1% | 5,170 | $5K | |
| 87088 | <1% | 1,231 | $5K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 766 | $4K |
| 82043 | <1% | 981 | $4K | |
| 87340 | <1% | 435 | $4K | |
| 73560 | <1% | 441 | $4K | |
| 86704 | <1% | 331 | $4K | |
| 73200 | <1% | 52 | $4K | |
| 83690 | <1% | 1,887 | $4K | |
| 86706 | <1% | 460 | $4K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 845 | $4K |
| 90715 | <1% | 1,181 | $4K | |
| 81003 | <1% | 2,800 | $4K | |
| 76882 | <1% | 202 | $4K | |
| 80050 | General health panel | <1% | 118 | $4K |
| 73090 | <1% | 310 | $3K | |
| 36591 | <1% | 93 | $3K | |
| 72070 | <1% | 159 | $3K | |
| 93226 | <1% | 66 | $3K | |
| 72131 | <1% | 42 | $3K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 234 | $3K |
| 74174 | <1% | 13 | $3K | |
| 81001 | <1% | 1,953 | $3K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 306 | $3K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 64 | $3K |
| 73140 | <1% | 240 | $3K | |
| 83883 | <1% | 82 | $3K | |
| 87522 | Neg quan hep c or qual rna | <1% | 124 | $3K |
| 82746 | <1% | 415 | $3K | |
| 96367 | <1% | 157 | $3K | |
| 82330 | <1% | 695 | $2K | |
| 87077 | <1% | 645 | $2K | |
| C1769 | Guide wire | <1% | 87 | $2K |
| 86682 | <1% | 44 | $2K | |
| 93975 | <1% | 27 | $2K | |
| 87040 | <1% | 259 | $2K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 14 | $2K |
| 73060 | <1% | 203 | $2K | |
| 85384 | <1% | 454 | $2K | |
| 80354 | <1% | 130 | $2K | |
| 82378 | <1% | 224 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 138 | $2K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 194 | $2K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 57 | $2K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 12 | $2K |
| 85379 | <1% | 413 | $2K | |
| 87186 | <1% | 485 | $2K | |
| 86140 | <1% | 961 | $2K | |
| 85652 | <1% | 1,020 | $2K | |
| 93225 | <1% | 68 | $2K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 7,561 | $2K |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 13 | $2K |
| 85007 | <1% | 662 | $1K | |
| 87467 | <1% | 122 | $1K | |
| 72050 | <1% | 39 | $1K | |
| 93926 | <1% | 16 | $1K | |
| 72170 | <1% | 102 | $1K | |
| 82550 | <1% | 375 | $1K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 16 | $1K |
| 74018 | <1% | 77 | $1K | |
| 76000 | <1% | 286 | $1K | |
| 84439 | <1% | 214 | $917.30 | |
| 87070 | <1% | 369 | $907.77 | |
| 73120 | <1% | 87 | $893.14 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 2,166 | $852.66 |
| 84165 | <1% | 118 | $825.23 | |
| 88342 | <1% | 310 | $813.43 | |
| OP270 | <1% | 61 | $730.48 | |
| 86787 | <1% | 42 | $730.21 | |
| 94618 | <1% | 76 | $705.14 | |
| 84295 | <1% | 1,348 | $684.25 | |
| 82784 | <1% | 44 | $674.57 | |
| 84132 | <1% | 1,410 | $666.86 | |
| 87205 | <1% | 369 | $639.60 | |
| 82565 | <1% | 290 | $639.54 | |
| 84156 | <1% | 264 | $622.91 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 6,873 | $598.95 |
| 73600 | <1% | 67 | $571.13 | |
| 76937 | <1% | 137 | $564.49 | |
| 86593 | <1% | 128 | $550.20 | |
| J2704 | Injection, propofol, 10 mg | <1% | 8,169 | $541.96 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,901 | $533.48 |
| G0239 | Therapeutic procedures to improve respiratory function or increase strength or endurance of respiratory muscles, two or more individuals (includes monitoring) | <1% | 47 | $530.61 |
| 11043 | <1% | 16 | $512.34 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 603 | $508.80 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 312 | $505.06 |
| 92134 | <1% | 315 | $477.15 | |
| 85045 | <1% | 198 | $471.23 | |
| 81015 | <1% | 325 | $465.03 | |
| 36430 | <1% | 14 | $464.38 | |
| 94060 | <1% | 26 | $454.00 | |
| 84436 | <1% | 101 | $452.55 | |
| 73100 | <1% | 31 | $440.66 | |
| 84479 | <1% | 102 | $426.87 | |
| 82375 | <1% | 188 | $411.06 | |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 34 | $407.57 |
| 84403 | <1% | 28 | $403.65 | |
| 82947 | <1% | 672 | $361.01 | |
| S5000 | Prescription drug, generic | <1% | 52 | $359.65 |
| 87081 | <1% | 106 | $342.30 | |
| 73620 | <1% | 46 | $308.21 | |
| 82248 | <1% | 103 | $305.73 | |
| 86160 | <1% | 20 | $297.78 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,570 | $292.61 |
| 72190 | <1% | 14 | $291.62 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 13 | $268.97 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,632 | $258.50 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,338 | $248.86 |
| 84550 | <1% | 78 | $238.55 | |
| J3490 | Unclassified drugs | <1% | 3,066 | $210.69 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 563 | $205.94 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,627 | $204.62 |
| 85018 | <1% | 703 | $202.84 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,458 | $198.22 |
| 86038 | <1% | 29 | $185.26 | |
| 82105 | <1% | 13 | $171.88 | |
| 82010 | <1% | 89 | $161.38 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 129 | $151.23 |
| 90686 | <1% | 13 | $150.34 | |
| 83615 | <1% | 204 | $143.31 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 543 | $142.32 |
| 83050 | <1% | 188 | $139.89 | |
| 86762 | <1% | 12 | $128.63 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 60 | $106.02 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,034 | $101.35 |
| J1815 | Injection, insulin, per 5 units | <1% | 591 | $100.14 |
| 80197 | <1% | 111 | $97.50 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 514 | $68.90 |
| G0008 | Administration of influenza virus vaccine | <1% | 92 | $68.30 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 817 | $66.04 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 417 | $58.39 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 236 | $57.92 |
| 80349 | <1% | 18 | $53.83 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,047 | $49.14 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,128 | $48.19 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 768 | $47.23 |
| 84425 | <1% | 26 | $46.90 | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 34 | $35.00 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 176 | $29.04 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 753 | $28.55 |
| 85008 | <1% | 130 | $23.55 | |
| 92133 | <1% | 16 | $21.52 | |
| 87015 | <1% | 13 | $20.19 | |
| 85014 | <1% | 49 | $19.38 | |
| 90662 | <1% | 12 | $14.63 | |
| 76376 | <1% | 15 | $14.26 | |
| 99201 | <1% | 101 | $14.12 | |
| 84460 | <1% | 17 | $13.48 | |
| 99152 | <1% | 14 | $11.39 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 14 | $10.44 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 4,827 | $10.37 |
| 97161 | <1% | 13 | $9.86 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 14 | $9.58 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 167 | $6.61 |
| 88304 | <1% | 41 | $3.17 | |
| 82247 | <1% | 16 | $1.63 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 1,060 | $0.00 |
| J0736 | Injection, clindamycin phosphate, 300 mg | 0% | 28 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 128 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 162 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 921 | $0.00 |
| S0028 | Injection, famotidine, 20 mg | 0% | 445 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 94 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 271 | $0.00 |
| H0034 | Medication training and support, per 15 minutes | 0% | 179 | $0.00 |
| H0015 | Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education | 0% | 3,125 | $0.00 |
| 87481 | 0% | 28 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 166 | $0.00 |
| 81513 | 0% | 30 | $0.00 | |
| 84450 | 0% | 15 | $0.00 | |
| J0670 | Injection, mepivacaine hydrochloride, per 10 ml | 0% | 15 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 13 | $0.00 |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 0% | 38 | $0.00 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | 0% | 365 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 423 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 1,066 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 194 | $0.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 38 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 269 | $0.00 |
| 36000 | 0% | 109 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 22 | $0.00 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 0% | 54 | $0.00 |
| V2632 | Posterior chamber intraocular lens | 0% | 42 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCCORMICK, THOMAS (AVP FINANCE)
| Provider | Location | Paid |
|---|---|---|
| Trustees of the University of Pennsylvania | Philadelphia, PA | $84.02M |
| The Pennsylvania Hospital of the University of Pennsylvania Health Sys | Phila, PA | $25.68M |
| Hall-Mercer Cmh-Mrc of Pennsylvania Hosp | Philadelphia, PA | $14.08M |
| Hall-Mercer Cmh-Mrc of PA Hosp | Phila, PA | $6.82M |
| Hospital of University of Pennsylvania | Phila, PA | $2.61M |
| Penn Presbyterian Medical CTR Detox Rehab | Phila, PA | $1.60M |
| Penn Presybyterian Medical Center | Phila, PA | $1.48M |
| The Pennsylvania Hospital of the University of Pennsylvania Health Sys | Philadelphia, PA | $69K |
| Thomas E Mccormick, MD, PC | Rutland, VT | $22K |
| Presbyterian Medical Center of the University of Pennsylvania Health S | Philadelphia, PA | $11K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.